A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia

Giles, 2002, Acute myeloid leukemia, Hematology (Am Soc Hematol Educ Program), 73, 10.1182/asheducation-2002.1.73 Shyam, 1985, Synthesis and evaluation of N,N’-bis(arylsulfonyl)hydrazines as antineoplastic agents, J Med Chem, 28, 525, 10.1021/jm00382a027 Shyam, 1986, 1,2-Bis(arylsulfonyl)hydrazines. 2. The influence of arylsulfonyl and aralkylsulfonyl substituents on antitumor and alkylating activity, J Med Chem, 29, 1323, 10.1021/jm00157a041 Shyam, 1987, 1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity, J Med Chem, 30, 2157, 10.1021/jm00394a040 Shyam, 1993, Synthesis and evaluation of 1-acyl-1,2-bis(methylsulfonyl)-2-(2-chloroethyl)hydrazines as antineoplastic agents, J Med Chem, 36, 3496, 10.1021/jm00075a002 Shyam, 1996, Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazines, J Med Chem, 39, 796, 10.1021/jm9505021 Pratviel, 1989, Cytotoxic and DNA-damaging effects of 1,2-bis(sulfonyl)hydrazines on human cells of the Mer+ and Mer- phenotype, Cancer Biochem Biophys, 10, 365 Penketh, 2000, Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas, Biochem Pharmacol, 59, 283, 10.1016/S0006-2952(99)00328-7 Finch, 2001, 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity, Cancer Res, 61, 3033 Ishiguro, 2005, Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine, Mol Cancer Ther, 4, 1755, 10.1158/1535-7163.MCT-05-0169 Briscoe, 1988, Preferential alkylation by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) of guanines with guanines as neighboring bases in DNA, Biochem Pharmacol, 37, 1061, 10.1016/0006-2952(88)90511-4 Lown, 1979, Nitrosourea-induced DNA single-strand breaks, Biochem Pharmacol, 28, 1631, 10.1016/0006-2952(79)90176-X Mao, 2002, Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rat, AAPS PharmSci, 4, E24, 10.1208/ps040424 Giles, 2004, A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia, Clin Cancer Res, 10, 2908, 10.1158/1078-0432.CCR-03-0738 Ferrara, 2004, Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia, Haematologica, 89, 998 Breems, 2005, Prognostic index for adult patients with acute myeloid leukemia in first relapse, J Clin Oncol, 23, 1969, 10.1200/JCO.2005.06.027 Godder, 2004, Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis, J Clin Oncol, 22, 3798, 10.1200/JCO.2004.12.142 Giles, 2005, Outcome of patients with acute myelogenous leukemia after second salvage therapy, Cancer, 104, 547, 10.1002/cncr.21187 Rowe, 2005, Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative Oncology Group Experience, ASH Annual Meeting Abstracts, 106, 546 Giles, 2005, Cloretazine (VNP40101M) is active in elderly untreated poor risk patients with acute myelogenous leukemia or high risk myelodysplasia, ASH Annual Meeting Abstracts, 106, 2786 Giles, 2005, Use of a disease-specific comorbidity index to describe elderly patients with acute myelogenous leukemia and high risk myelodysplasia enrolled in a phase II study of cloretazine (VNP40101M), ASH Annual Meeting Abstracts, 106, 2787